What are the indications, dosing regimens, contraindications, and monitoring requirements for Lamisil (terbinafine)?

Lamisil (Terbinafine): Clinical Overview

Primary Indication

Terbinafine is the first-line treatment for dermatophyte onychomycosis (fungal nail infections) and should be strongly preferred over other antifungal agents due to superior efficacy, lower relapse rates, and fewer drug interactions 1.

Indications

Terbinafine is indicated for:

• Onychomycosis (nail infections) - particularly dermatophyte infections caused by Trichophyton rubrum and T. mentagrophytes
• Tinea pedis (athlete's foot)
• Tinea corporis/cruris (ringworm of body/groin)
• Tinea capitis (scalp ringworm) in children

The drug demonstrates potent fungicidal activity against dermatophytes but has lower activity against Candida species compared to azole antifungals 1.

Dosing Regimens

Adults

For Onychomycosis:

• Fingernails: 250 mg once daily for 6 weeks
• Toenails: 250 mg once daily for 12-16 weeks
• Re-evaluate patients 3-6 months after treatment initiation; continue treatment if disease persists 1

For Tinea Pedis/Corporis/Cruris:

• 250 mg once daily for 2-4 weeks (though recent evidence suggests poor cure rates at standard doses for tinea corporis/cruris) 2

Topical Formulation:

• 1% cream applied once or twice daily for up to 2 weeks 3

Children (Age 1-12 years)

Terbinafine is not licensed for pediatric onychomycosis, but weight-based dosing is used:

• Dosing varies by weight (typically 62.5-250 mg/day for 4 weeks for tinea capitis)
• Baseline monitoring should be considered as it's off-label 1

Important: Absorption is not affected by food intake, unlike itraconazole 1.

Contraindications and Cautions

Absolute Contraindications:

• Active or chronic liver disease - rare but serious hepatotoxicity has been reported 1
• Severe renal impairment - terbinafine clearance is decreased 1

Relative Contraindications/Cautions:

• Pregnancy (topical formulation contraindicated) 1
• History of hepatitis or heavy alcohol consumption
• Pre-existing haematological abnormalities
• Psoriasis (can aggravate the condition) 1

Topical Use Warnings:

• For external use only
• Do not use on nails, scalp, in/near mouth or eyes, or for vaginal yeast infections 3

Monitoring Requirements

Baseline Testing (Recommended):

• Liver function tests (LFTs) - particularly in patients with:
  • History of heavy alcohol consumption
  • Previous hepatitis
  • Pre-existing liver disease
• Complete blood count (CBC) - in patients with history of haematological abnormalities 1

Ongoing Monitoring:

• Baseline monitoring should also be considered for children receiving off-label treatment 1
• Monitor for taste disturbance (can be permanent - patients must be warned) 1
• Watch for signs of serious adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis - though rare) 1

Adverse Effects

Common (incidence from postmarketing surveillance):

• Gastrointestinal effects (49%): nausea, diarrhea, taste disturbance
• Dermatological events (23%): rash, pruritus, urticaria, eczema
• Headache 1

Serious (rare, 0.04% incidence):

• Hepatotoxicity (usually in patients with pre-existing liver disease)
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis
• Subacute lupus-like syndrome
• Permanent taste disturbance 1

Drug Interactions

Terbinafine has minimal drug-drug interactions - a significant advantage over azole antifungals 1. The only potentially significant interaction is with drugs metabolized by cytochrome P450 2D6 isoenzyme 1.

Comparative Efficacy

Terbinafine demonstrates superior efficacy to itraconazole for dermatophyte onychomycosis:

• Complete cure rates: 55% (terbinafine) vs. 26% (itraconazole) at 72 weeks
• 5-year mycological cure without re-treatment: 46% (terbinafine) vs. 13% (itraconazole)
• Relapse rates significantly lower: 23% (terbinafine) vs. 53% (itraconazole) 1

Terbinafine is also more effective than griseofulvin with considerably shorter treatment duration 1.

Pharmacokinetic Advantages

• Fungicidal mechanism (only oral fungicidal antimycotic available) 1
• Strongly lipophilic - excellent distribution to skin and nails
• Detected in nails within 1 week of starting therapy
• Persists for 6 months after treatment completion - allowing for continued efficacy post-therapy 1

• 70% oral absorption, 99% protein binding 1

Common Pitfalls to Avoid

1. Don't use standard doses for resistant infections - recent evidence shows poor cure rates with 250 mg daily for tinea corporis/cruris; combination therapy with itraconazole may be needed for recalcitrant cases 2, 4

2. Don't forget to warn about permanent taste disturbance - though rare, this is a critical counseling point 1

3. Don't prescribe without baseline LFTs in at-risk patients - hepatotoxicity, while rare, can be serious 1

4. Don't expect immediate results - mycological cure rates actually improve after treatment cessation due to the drug's residual tissue effect 5

5. Don't use for Candida infections - terbinafine has poor activity against yeast species; azoles are preferred 1